North America Hepatitis Testing/Diagnosis Market, 2025–2035
The North America Hepatitis Testing/Diagnosis Market is experiencing significant expansion, primarily driven by increasing hepatitis cases, rising health awareness, supportive regulatory frameworks, and ongoing technology advancements. Diverse testing types, evolving applications, and distribution channels are reshaping the landscape. Major companies are investing in innovative diagnostics, automation, and rapid testing, leading to improved disease management, particularly in healthcare settings. The forecast points to robust growth, with investments in advanced molecular diagnostics and point-of-care solutions likely to dominate the market outlook through 2035.
Latest Market Dynamics
Key Drivers
- Rising prevalence of hepatitis B and C infections, particularly in the US and Canada, is driving demand for accurate and rapid diagnostic solutions. For example, Abbott Laboratories introduced new multiplex test panels in 2024, accelerating screening processes and expanding market reach.
- Government initiatives targeting hepatitis elimination and increased funding for public health screening programs are incentivizing technology adoption. Roche Diagnostics strengthened its partnerships with regional health authorities in 2024 to provide enhanced molecular diagnostic solutions.
Key Trends
- Growing adoption of point-of-care rapid testing is leading to faster and more accessible hepatitis diagnosis, especially in non-hospital settings. Siemens Healthineers, for instance, expanded its rapid test portfolio in early 2024.
- Integration of digital diagnostics and artificial intelligence (AI) for improved result interpretation and workflow efficiency. Thermo Fisher Scientific launched AI-enabled diagnostic platforms in 2024, enhancing data-driven patient management.
Key Opportunities
- Expanding telemedicine and home-based diagnostic models create opportunities for market players to introduce self-testing kits. In 2024, Bio-Rad Laboratories launched at-home hepatitis C RNA testing solutions.
- Growing demand for multiplex testing platforms allows simultaneous screening of multiple hepatitis types, increasing efficiency. Beckman Coulter (Danaher Corporation) recently developed comprehensive panels in partnership with public health labs.
Key Challenges
- Limited accessibility to advanced diagnostics in rural and underserved regions remains a barrier, affecting early detection rates. Ortho Clinical Diagnostics is piloting mobile lab solutions to address this gap in 2025.
- Variability in hepatitis screening recommendations and reimbursement policies across the US, Canada, and Mexico complicates market standardization. Hologic Inc. and partners are working on advocacy campaigns for unified testing protocols.
Key Restraints
- High cost associated with next-generation molecular testing platforms restricts adoption among small- and medium-sized healthcare organizations. Sysmex Corporation is attempting to address this via cost-efficient models.
- Stringent regulatory pathways slow down the approval and commercialization of innovative diagnostic products. QIAGEN faces ongoing regulatory review challenges for its new multiplex assay, delaying entry in the US market.
Market Share by Type, 2025
The North America Hepatitis Testing/Diagnosis Market by type in 2025 is led by Hepatitis B and Hepatitis C testing, together making up the bulk of total market share. Increased awareness, public health initiatives, and rising incidence rates, particularly among high-risk populations, are propelling the demand for these test types. Hepatitis A, D, and E constitute smaller shares, largely due to lower prevalence and targeted vaccination campaigns. The 'Others' segment captures specialized testing and rare hepatitis strains.
Market Share by Applications, 2025
In 2025, hospitals & clinics hold the highest share of hepatitis testing/diagnosis applications in North America due to integrated screening programs and robust diagnostic infrastructure. Blood banks follow closely due to mandated routine testing. Diagnostic laboratories and research institutes contribute significant shares as investments in public health and clinical research expand. Public health programs and other applications cover mass screening and targeted initiatives to reach at-risk populations.
Market Revenue (USD Million), 2020–2035
Market revenue in North America for hepatitis testing/diagnosis has shown steady growth from 2020, with significant acceleration post-2023 due to new testing technologies and greater healthcare spending. The 2025 market size is projected at 1,220 million USD, with further increases expected as prevention and early detection efforts expand. By 2035, revenue is forecast to reach 2,960 million USD, indicating a CAGR aligned with the sector’s rising health priorities.
Market YOY (%), 2020–2035
The year-on-year (YOY) growth rate of the North America hepatitis testing/diagnosis market demonstrates moderate expansion from 2020–2025, with YOY growth rising from 7.8% in 2021 to a peak of 9% by 2026, driven by improved diagnostics and healthcare frameworks. Growth rates are expected to stabilize between 8–10% through 2035 as innovative products and expanded screening sustain momentum.
Market Share by Regions, 2025
In 2025, the regional breakdown of the North America hepatitis testing/diagnosis market shows the US accounting for the dominant share, reflecting its large population, healthcare expenditure, and screening mandates. Canada follows, driven by strong public health programs, while Mexico presents emerging growth through expanded access and awareness campaigns. This distribution underlines the impact of national healthcare strategies and varying disease prevalence across North America.
Market Players Share (%), 2025
In 2025, the leading market players in North America Hepatitis Testing/Diagnosis include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, together capturing the majority share as a result of robust portfolios and continuous R&D. Other notable companies such as Bio-Rad Laboratories and Danaher Corporation maintain significant presence with strong technological and strategic advances. Consolidation and innovation are driving performance in this competitive landscape.
Market Buyers Share (%), 2025
Hospitals and clinics form the bulk of buyers in the North America Hepatitis Testing/Diagnosis Market in 2025, reflecting their position as primary care and diagnostic centers. Blood banks, public health agencies, and diagnostic labs are also substantial buyers, driven by regulatory screening requirements and prevention initiatives. The diversification in buyer types demonstrates the widespread need for robust hepatitis diagnostics across North America’s healthcare ecosystem.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1220 |
| Regions | US, Canada, Mexico |
| Segments | By Type (Hepatitis B, Hepatitis C, Hepatitis A, Hepatitis D, Hepatitis E, Others), By Application (Blood Banks, Hospitals & Clinics, Diagnostic Laboratories, Research Institutes, Others), By Distribution Channels (Direct Tender, Retail Sales, Online Sales, Others), By Technology (ELISA, Rapid Diagnostic Tests, PCR, Immunoassays, Radioimmunoassay, Others), By Organization Size (Small, Medium, Large) |
| Players | Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Bio-Rad Laboratories, BioMerieux, Danaher Corporation (Beckman Coulter), QIAGEN, Ortho Clinical Diagnostics, Hologic Inc., Sysmex Corporation, Grifols, Trinity Biotech, Abbott Rapid Diagnostics, Fujirebio, Thermo Fisher Scientific |
Key Recent Developments
- June 2024: Roche Diagnostics announced a strategic partnership with Canadian public health officials to expand hepatitis C RNA testing access.
- July 2024: Bio-Rad Laboratories launched their first at-home hepatitis testing kit across selected US states targeting underserved populations.
- August 2024: Siemens Healthineers introduced a digital workflow-integrated rapid hepatitis B surface antigen testing solution.
- September 2024: QIAGEN initiated a US multi-center trial for their latest multiplex hepatitis virus screening assay.
- October 2024: Danaher Corporation (Beckman Coulter) received FDA clearance for a new all-in-one hepatitis diagnostics panel.
